ANTIMALARIALS
Identifieur interne : 002287 ( Main/Exploration ); précédent : 002286; suivant : 002288ANTIMALARIALS
Auteurs : Marta J. Van Beek ; Warren W. PietteSource :
- Dermatologic Clinics [ 0733-8635 ] ; 2001.
English descriptors
- Teeft :
- Acad, Acad dermatol, American experience, American soldiers, Antimalarial, Antimalarial drugs, Antimalarial retinopathy, Antimalarial therapy, Arch dermatol, Arch dermatol syphil, Arthritis, Arthritis rheum, Atabrine, Baltimore lupus cohort, Beek, Beek piette, British experience, Canadian hydroxychloroquine study group, Cardiovascular arrest, Cessation, Chloroquine, Chloroquine phosphate, Chloroquine therapy, Collapse convulsions, Combination therapy, Common reason, Corneal deposition, Corneal deposits, Cumulative dosage, Cutanea, Cutaneous, Cutaneous lupus, Cutaneous manifestations, Cutaneous psoriatic flares, Cutaneous sarcoidosis, Daily dosage, Dermatitis, Dermatol, Diabetes mellitus, Discoid lupus erythematosus, Dos, Dosage, Drug cessation, Drug discontinuation, Drug interactions, Drug molecules, Drug therapy, Eruption, Erythematosus, Erythrocyte sedimentation rate, Gastrointestinal tract, Hydroxychloroquine, Hydroxychloroquine retinopathy, Hydroxychloroquine sulfate, Hypersensitivity liver, Ideal body weight, Iowa hospitals, Lichenoid, Lichenoid drug eruption, Lupus, Lupus erythematosus, Lupus patients, Medication, Nail beds, Ocular, Ocular safety, Ocular toxicity, Oral chloroquine, Other disease, Paracentral scotomas, Peak plasma levels, Piette, Plasma proteins, Platelet, Platelet aggregation, Porphyria, Porphyria cutanea tarda, Psoriasis, Psoriatic, Psoriatic arthritis, Psychosis, Quinacrine, Randomized study, Renal, Retinal, Retinal disease, Retinal toxicity, Retinopathy, Rheum, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Semin arthritis rheum, Side effects, Solar urticaria, Successful treatment, Such eruptions, Symptom, Systemic lupus erythematosus, Tarda, Therapy, Thrombotic events, Toxic psychosis, Toxicity.
Abstract
Antimalarial medications have become the parenteral drugs of choice for treating the cutaneous manifestations of lupus erythematosus (LE). The immune-modulating activity of these agents has made them useful in a variety of other dermatoses. With prudent dosage and monitoring, these agents can be used safely and effectively in the treatment and management of dermatologic disease.
Url:
DOI: 10.1016/S0733-8635(05)70236-9
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000017
- to stream Istex, to step Curation: 000017
- to stream Istex, to step Checkpoint: 001111
- to stream Main, to step Merge: 002311
- to stream Main, to step Curation: 002287
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>ANTIMALARIALS</title><author><name sortKey="Van Beek, Marta J" sort="Van Beek, Marta J" uniqKey="Van Beek M" first="Marta J." last="Van Beek">Marta J. Van Beek</name></author><author><name sortKey="Piette, Warren W" sort="Piette, Warren W" uniqKey="Piette W" first="Warren W." last="Piette">Warren W. Piette</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BC8D7404EE8870FFDC4EB29CC9D33D0164AD29B3</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0733-8635(05)70236-9</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-20TL838W-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000017</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000017</idno><idno type="wicri:Area/Istex/Curation">000017</idno><idno type="wicri:Area/Istex/Checkpoint">001111</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001111</idno><idno type="wicri:Area/Main/Merge">002311</idno><idno type="wicri:Area/Main/Curation">002287</idno><idno type="wicri:Area/Main/Exploration">002287</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">ANTIMALARIALS</title><author><name sortKey="Van Beek, Marta J" sort="Van Beek, Marta J" uniqKey="Van Beek M" first="Marta J." last="Van Beek">Marta J. Van Beek</name></author><author><name sortKey="Piette, Warren W" sort="Piette, Warren W" uniqKey="Piette W" first="Warren W." last="Piette">Warren W. Piette</name></author></analytic><monogr></monogr><series><title level="j">Dermatologic Clinics</title><title level="j" type="abbrev">DET</title><idno type="ISSN">0733-8635</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="147">147</biblScope><biblScope unit="page" to="160">160</biblScope></imprint><idno type="ISSN">0733-8635</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0733-8635</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Acad dermatol</term><term>American experience</term><term>American soldiers</term><term>Antimalarial</term><term>Antimalarial drugs</term><term>Antimalarial retinopathy</term><term>Antimalarial therapy</term><term>Arch dermatol</term><term>Arch dermatol syphil</term><term>Arthritis</term><term>Arthritis rheum</term><term>Atabrine</term><term>Baltimore lupus cohort</term><term>Beek</term><term>Beek piette</term><term>British experience</term><term>Canadian hydroxychloroquine study group</term><term>Cardiovascular arrest</term><term>Cessation</term><term>Chloroquine</term><term>Chloroquine phosphate</term><term>Chloroquine therapy</term><term>Collapse convulsions</term><term>Combination therapy</term><term>Common reason</term><term>Corneal deposition</term><term>Corneal deposits</term><term>Cumulative dosage</term><term>Cutanea</term><term>Cutaneous</term><term>Cutaneous lupus</term><term>Cutaneous manifestations</term><term>Cutaneous psoriatic flares</term><term>Cutaneous sarcoidosis</term><term>Daily dosage</term><term>Dermatitis</term><term>Dermatol</term><term>Diabetes mellitus</term><term>Discoid lupus erythematosus</term><term>Dos</term><term>Dosage</term><term>Drug cessation</term><term>Drug discontinuation</term><term>Drug interactions</term><term>Drug molecules</term><term>Drug therapy</term><term>Eruption</term><term>Erythematosus</term><term>Erythrocyte sedimentation rate</term><term>Gastrointestinal tract</term><term>Hydroxychloroquine</term><term>Hydroxychloroquine retinopathy</term><term>Hydroxychloroquine sulfate</term><term>Hypersensitivity liver</term><term>Ideal body weight</term><term>Iowa hospitals</term><term>Lichenoid</term><term>Lichenoid drug eruption</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus patients</term><term>Medication</term><term>Nail beds</term><term>Ocular</term><term>Ocular safety</term><term>Ocular toxicity</term><term>Oral chloroquine</term><term>Other disease</term><term>Paracentral scotomas</term><term>Peak plasma levels</term><term>Piette</term><term>Plasma proteins</term><term>Platelet</term><term>Platelet aggregation</term><term>Porphyria</term><term>Porphyria cutanea tarda</term><term>Psoriasis</term><term>Psoriatic</term><term>Psoriatic arthritis</term><term>Psychosis</term><term>Quinacrine</term><term>Randomized study</term><term>Renal</term><term>Retinal</term><term>Retinal disease</term><term>Retinal toxicity</term><term>Retinopathy</term><term>Rheum</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Semin arthritis rheum</term><term>Side effects</term><term>Solar urticaria</term><term>Successful treatment</term><term>Such eruptions</term><term>Symptom</term><term>Systemic lupus erythematosus</term><term>Tarda</term><term>Therapy</term><term>Thrombotic events</term><term>Toxic psychosis</term><term>Toxicity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Antimalarial medications have become the parenteral drugs of choice for treating the cutaneous manifestations of lupus erythematosus (LE). The immune-modulating activity of these agents has made them useful in a variety of other dermatoses. With prudent dosage and monitoring, these agents can be used safely and effectively in the treatment and management of dermatologic disease.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Piette, Warren W" sort="Piette, Warren W" uniqKey="Piette W" first="Warren W." last="Piette">Warren W. Piette</name><name sortKey="Van Beek, Marta J" sort="Van Beek, Marta J" uniqKey="Van Beek M" first="Marta J." last="Van Beek">Marta J. Van Beek</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002287 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002287 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BC8D7404EE8870FFDC4EB29CC9D33D0164AD29B3
|texte= ANTIMALARIALS
}}
| This area was generated with Dilib version V0.6.33. |  |